Supplemental Table 2. Immune checkpoint therapy associated markers among *KRAS*-mutated tumors (A), comparison of these markers between KRAS G12C and all other subtypes (B) and further comparison between G12C, G12A and G13D subtypes (C). * represents p or q values <0.05.

A.

Test	KRAS WT %	G12V %	G12A %	G12C %	G13 %	Q61 %	G12D %	G12 Other %	P-value	Q-value
TMB-H	30.1%	34.7%	27.3%	36.4%	50.0%	28.2%	19.1%	43.7%	p<0.0001*	q<0.0001*
MSI-H/dMMR	0.7%	0.6%	0.7%	0.4%	0.6%	1.6%	0.3%	0.5%	0.251	0.766
PD-L1 TPS >1%	52.1%	58.2%	61.5%	65.5%	57.7%	62.6%	62.7%	56.4%	0.004*	0.06
PD-L1 TPS > 50%	25.9%	35.2%	36.3%	41.3%	35.0%	36.7%	35.3%	28.2%	0.002*	0.038*

B.

Test	G12C Positive	G12C Negative	Total	% G12C mt	non G12C Positive	non G12C Negative	Total	% non G12C mt	P-value	Q-value
TMB-H	408	712	1120	36.4%	518	1115	1633	31.7%	0.010219*	0.012774*
MSI-H/dMMR	8	1833	1841	0.4%	17	2663	2680	0.6%	0.373472	0.373472
PD-L1 TPS >1%	1118	588	1706	65.5%	1493	996	2489	60.0%	0.000271*	0.000451*
PD-L1 TPS >50%	704	1002	1706	41.3%	870	1619	2489	35.0%	3.36E-05*	8.66E-05*

C.

Test	G12A %	G12C %	P value (G12A vs G12C)	Q value (G12A vs G12C)	G13D %	P value (G12A/G12C/G13D)	Q value (G12A/G12C/G13D)
TMB-H	27.27%	36.43%	0.018*	0.272	46.27%	0.011*	0.274
MSI-H/dMMR	0.70%	0.40%	0.555	0.788	1.70%	0.172	0.805
PD-L1 TPS >1%	61.50%	65.50%	0.197	0.787	65.70%	0.43	0.912